高级检索
当前位置: 首页 > 详情页

Upregulation of miRNA-140-5p inhibits inflammatory cytokines in acute lung injury through the MyD88/NF-kappa B signaling pathway by targeting TLR4

| 导出 | |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, Sichuan 610041 [2]Department of Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120 [3]Surgical Center, Sichuan Cancer Hospital, Chengdu, Sichuan 610041, P.R. China
出处:
ISSN:

关键词: microRNA-140-5p acute lung injury inflammation Toll-like receptor 4 myeloid differentiation primary response 88 nuclear factor-kappa B

摘要:
The present study was designed to determine the effect of miR-140-5p on acute lung injury (ALI) and the associated inflammation induced. As a result, miR-140-5p expression in mice with ALI was suppressed when compared with the normal group. Downregulation of miR-140-5p increased the levels of inflammatory factors induced by ALI [including tumor necrosis factor-alpha, interleukin (IL)-1 beta, IL-6 and myeloperoxidase] in an in vitro model of human lung A549 cells. Downregulation of miR-140-5p also induced the protein expression of Toll-like receptor 4 (TLR4), myeloid differentiation primary response 88 (MyD88) and nuclear factor (NF)-kappa B in an in vitro model. Overexpression of miR-140-5p reduced the levels of inflammation in the in vitro model of ALI via the suppression of the TLR4/MyD88/NF-kappa B signaling pathway. The inhibition of TLR4 using a TLR4 inhibitor reduced the proinflammation effects of anti-miR-140-5p in the in vitro model of ALI. The NF-kappa B inhibitor also inhibited the proinflammation effects of anti-miR-140-5p in the in vitro model of ALI. Overall, the results of the present study indicated that miR-140-5p inhibited ALI-induced inflammation via the TLR4/MyD88/NF-kappa B signaling pathway.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验
JCR分区:
出版当年[2018]版:
Q4 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, Sichuan 610041
通讯作者:
通讯机构: [3]Surgical Center, Sichuan Cancer Hospital, Chengdu, Sichuan 610041, P.R. China [*1]Surgical Center, Sichuan Cancer Hospital, 55, Section 4, South Ren min Road, Chengdu, Sichuan 610041, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:52808 今日访问量:2 总访问量:4561 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号